BACKGROUND: Atopic dermatitis (AD) is a common inflammatory skin disease exhibiting a predominantly T(H)2/"T22" immune activation and a defective epidermal barrier. Narrow-band UVB (NB-UVB) is considered an efficient treatment for moderate-to-severe AD. In patients with psoriasis, NB-UVB has been found to suppress T(H)1/T(H)17 polarization, with subsequent reversal of epidermal hyperplasia. The immunomodulatory effects of this treatment are largely unknown in patients with AD. OBJECTIVE: We sought to evaluate the effects of NB-UVB on immune and barrier abnormalities in patients with AD, aiming to establish reversibility of disease and biomarkers of therapeutic response. METHODS: Twelve patients with moderate-to-severe chronic AD received NB-UVB phototherapy 3 times weekly for up to 12 weeks. Lesional and nonlesional skin biopsy specimens were obtained before and after treatment and evaluated by using gene expression and immunohistochemistry studies. RESULTS: All patients had at least a 50% reduction in SCORAD index scores with NB-UVB phototherapy. The T(H)2, T22, and T(H)1 immune pathways were suppressed, and measures of epidermal hyperplasia and differentiation normalized. The reversal of disease activity was associated with elimination of inflammatory leukocytes and T(H)2/T22- associated cytokines and chemokines and normalized expression of barrier proteins. CONCLUSIONS: Our study shows that resolution of clinical disease in patients with chronic AD is accompanied by reversal of both the epidermal defects and the underlying immune activation. We have defined a set of biomarkers of disease response that associate resolved T(H)2 and T22 inflammation in patients with chronic AD with reversal of barrier pathology. By showing reversal of the AD epidermal phenotype with a broad immune-targeted therapy, our data argue against a fixed genetic phenotype.
BACKGROUND:Atopic dermatitis (AD) is a common inflammatory skin disease exhibiting a predominantly T(H)2/"T22" immune activation and a defective epidermal barrier. Narrow-band UVB (NB-UVB) is considered an efficient treatment for moderate-to-severe AD. In patients with psoriasis, NB-UVB has been found to suppress T(H)1/T(H)17 polarization, with subsequent reversal of epidermal hyperplasia. The immunomodulatory effects of this treatment are largely unknown in patients with AD. OBJECTIVE: We sought to evaluate the effects of NB-UVB on immune and barrier abnormalities in patients with AD, aiming to establish reversibility of disease and biomarkers of therapeutic response. METHODS: Twelve patients with moderate-to-severe chronic AD received NB-UVB phototherapy 3 times weekly for up to 12 weeks. Lesional and nonlesional skin biopsy specimens were obtained before and after treatment and evaluated by using gene expression and immunohistochemistry studies. RESULTS: All patients had at least a 50% reduction in SCORAD index scores with NB-UVB phototherapy. The T(H)2, T22, and T(H)1 immune pathways were suppressed, and measures of epidermal hyperplasia and differentiation normalized. The reversal of disease activity was associated with elimination of inflammatory leukocytes and T(H)2/T22- associated cytokines and chemokines and normalized expression of barrier proteins. CONCLUSIONS: Our study shows that resolution of clinical disease in patients with chronic AD is accompanied by reversal of both the epidermal defects and the underlying immune activation. We have defined a set of biomarkers of disease response that associate resolved T(H)2 and T22 inflammation in patients with chronic AD with reversal of barrier pathology. By showing reversal of the AD epidermal phenotype with a broad immune-targeted therapy, our data argue against a fixed genetic phenotype.
Authors: Johanna M Kwakkel-van Erp; Inge M Haeck; Annelieke W M Paantjens; Ed A van de Graaf; Walter G J van Ginkel; Mirjam J Knol; Marjolein S de Bruin-Weller; Jan-Willem J Lammers; Edward F Knol; Carla Bruijnzeel-Koomen; Henny G Otten Journal: J Am Acad Dermatol Date: 2010-09 Impact factor: 11.527
Authors: Barbara M Aufiero; Harvinder Talwar; Chen Young; Murali Krishnan; James S Hatfield; Hae Kyung Lee; Henry K Wong; Iltefat Hamzavi; George J Murakawa Journal: J Photochem Photobiol B Date: 2005-11-23 Impact factor: 6.252
Authors: Michael D Howell; Natalija Novak; Thomas Bieber; Saveria Pastore; Giampiero Girolomoni; Mark Boguniewicz; Joanne Streib; Cathy Wong; Richard L Gallo; Donald Y M Leung Journal: J Invest Dermatol Date: 2005-10 Impact factor: 8.551
Authors: Hideki Fujita; Kristine E Nograles; Toyoko Kikuchi; Juana Gonzalez; John A Carucci; James G Krueger Journal: Proc Natl Acad Sci U S A Date: 2009-12-08 Impact factor: 11.205
Authors: Michael D Howell; Heather R Fairchild; Byung Eui Kim; Lianghua Bin; Mark Boguniewicz; Jasmina S Redzic; Kirk C Hansen; Donald Y M Leung Journal: J Invest Dermatol Date: 2008-04-03 Impact factor: 8.551
Authors: Seung P Hong; Min J Kim; Min-Young Jung; Hyerin Jeon; Jawoong Goo; Sung K Ahn; Seung H Lee; Peter M Elias; Eung H Choi Journal: J Invest Dermatol Date: 2008-06-26 Impact factor: 8.551
Authors: Mark G Lebwohl; James Q Del Rosso; William Abramovits; Brian Berman; David E Cohen; Emma Guttman; Anthony J Mancini; Lawrence A Schachner Journal: J Clin Aesthet Dermatol Date: 2013-07
Authors: Saakshi Khattri; Patrick M Brunner; Sandra Garcet; Robert Finney; Steven R Cohen; Margeaux Oliva; Riana Dutt; Judilyn Fuentes-Duculan; Xiuzhong Zheng; Xuan Li; Kathleen M Bonifacio; Norma Kunjravia; Israel Coats; Inna Cueto; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; James G Krueger; Emma Guttman-Yassky Journal: Exp Dermatol Date: 2016-08-09 Impact factor: 3.960